Arik Makovitzki
Overview
Explore the profile of Arik Makovitzki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cohen N, Simon I, Hazan O, Tal A, Tzadok H, Levin L, et al.
Front Bioeng Biotechnol
. 2024 Mar;
12:1333548.
PMID: 38449674
The COVID-19 pandemic has led to high global demand for vaccines to safeguard public health. To that end, our institute has developed a recombinant viral vector vaccine utilizing a modified...
2.
Aftalion M, Tidhar A, Vagima Y, Gur D, Zauberman A, Holtzman T, et al.
Vaccines (Basel)
. 2023 Mar;
11(3).
PMID: 36992165
In a recent study, we demonstrated that vaccination with the polymeric F1 capsule antigen of the plague pathogen led to the rapid induction of a protective humoral immune response via...
3.
Nechooshtan R, Ehrlich S, Vitikainen M, Makovitzki A, Dor E, Marcus H, et al.
Vaccines (Basel)
. 2022 Dec;
10(12).
PMID: 36560529
SARS-CoV-2 is evolving with increased transmission, host range, pathogenicity, and virulence. The original and mutant viruses escape host innate (Interferon) immunity and adaptive (Antibody) immunity, emphasizing unmet needs for high-yield,...
4.
Makovitzki A, Jayson A, Oren Z, Lerer E, Kafri Y, Dor E, et al.
BioTech (Basel)
. 2022 Jul;
10(4).
PMID: 35822799
The COVID-19 pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) increases the need for a rapid development of efficient vaccines. Among other vaccines in clinical trials, a recombinant...
5.
Lerer E, Oren Z, Kafri Y, Adar Y, Toister E, Cherry L, et al.
BioTech (Basel)
. 2022 Jul;
10(4).
PMID: 35822796
This study reports a highly efficient, rapid one-step purification process for the production of the recombinant vesicular stomatitis virus-based vaccine, rVSV-∆G-spike (rVSV-S), recently developed by the Israel Institute for Biological...
6.
Vagima Y, Gur D, Aftalion M, Moses S, Levy Y, Makovitzki A, et al.
Viruses
. 2022 Apr;
14(4).
PMID: 35458417
Plague pandemics and outbreaks have killed millions of people during the history of humankind. The disease, caused by the bacteria , is currently treated effectively with antibiotics. However, in the...
7.
Rosen O, Jayson A, Dor E, Epstein E, Makovitzki A, Cherry L, et al.
J Virol Methods
. 2022 Feb;
303:114498.
PMID: 35217103
The spike glycoprotein mediates virus binding to the host cells and is a key target for vaccines development. One SARS-CoV-2 vaccine is based on vesicular stomatitis virus (VSV), in which...
8.
Makovitzki A, Lerer E, Kafri Y, Adar Y, Cherry L, Lupu E, et al.
Vaccine
. 2021 Nov;
39(48):7044-7051.
PMID: 34756612
rVSV-Spike (rVSV-S) is a recombinant viral vaccine candidate under development to control the COVID-19 pandemic and is currently in phase II clinical trials. rVSV-S induces neutralizing antibodies and protects against...
9.
Barbhuiya N, Singh S, Makovitzki A, Narkhede P, Oren Z, Adar Y, et al.
Materials (Basel)
. 2021 Jul;
14(12).
PMID: 34207716
Interest in the pathogenesis, detection, and prevention of viral infections has increased broadly in many fields of research over the past year. The development of water treatment technology to combat...
10.
Falach R, Sapoznikov A, Evgy Y, Aftalion M, Makovitzki A, Agami A, et al.
Toxins (Basel)
. 2020 Jun;
12(6).
PMID: 32481526
Ricin, a plant-derived toxin originating from the seeds of (castor bean plant), is one of the most lethal toxins known. To date, there is no approved post-exposure therapy for ricin...